what is glp-1 drugs for weight loss GLP-1s Loss: You Need to Know Americans Need More Information About

COA dates help lab teams assess whether a record belongs to the current lot and whether the listing, label, and batch file tell the same story

Rapid antidepressant effects of deep brain stimulation of the pre-frontal cortex in an animal model of treatment-resistant depression

Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP1 and amylin analogues owenhaskins Dec 19, 2025 2 min read Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition

Phase I study of trastuzumab-DM1, an HER2 antibodydrug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

This paper is based on a presentation given at the Annual Meeting of the Society for the Study of Ingestive Behavior in July 2021 and provides a personal view on some of the milestones in the discovery of amylin as a constituent of pancreatic islet amyloid deposits, as a pancreatic beta-cell hormone, and on its role in physiology and pathophysiology

The study showed that, although not at statistical significance, there was a trend for a lower incidence of bronchitis, pneumonia, upper respiratory lung infection, lung squamous cell carcinoma, acute respiratory failure, asthma, chronic obstructive lung disease (COPD), pulmonary fibrosis, and lung oedema